b_c8b523ffbe20ceb07dc1a8a8e712356fTRIFIT_11-1747-X_SLEEVE_11-0541-X_058_small-2.jpg

DonJoy Revolutionizes Osteoarthritis Bracing with Introduction of “TriFit” Knee Brace

Posted On March 15, 2017 By OrthoSpineNews In Extremities /  

March 15, 2017

SAN DIEGO–(BUSINESS WIRE)–DJO Global, Inc., a leading global provider of medical technologies designed to get and keep people moving, today launched OA Reaction TriFit™ Knee brace from DonJoy – the company’s latest OA knee brace designed to provide much needed pain relief to those who suffer from the incurable, degenerative joint disease that affects more than 11 million1 Americans. TriFit, from DonJoy, is designed to provide pain relief to individuals who suffer from moderate to severe Knee OA caused from an active lifestyle (overuse), suffer from excess body weight (obesity) or who are suffering from the effects of aging.

The most common type of arthritis, Knee OA, occurs when the cartilage which provides cushioning within the joints, wears down over time, resulting in bone-on-bone rubbing, which causes stiffness, pain, swelling, decreased mobility and bone spurs. OA is a condition that develops slowly, yet can become increasingly worse over time and may result in additional medical issues such as diabetes, heart disease and vascular problems if not addressed in its early stages. The knee is commonly affected by OA at a cost of $128 billion2 to healthcare.

“With more than 40 percent of knee replacements occurring in patients over the age of 65 and the average onset of knee OA occurring at the age of 553, there is an inherent need for non-invasive, non-addictive methods to control pain and to support maintaining an active lifestyle,” said Steve Ingel, President of Bracing & Supports at DJO Global. “With the onset of knee pain people tend to reduce their activity levels when the most important thing they can do to slow the progression of the disease is to remain active. Fortunately, the advanced low profile comfort of TriFit, provides a solution that aids in pain relief and helps keep patients moving.”

TriFit by DonJoy features three unique technologies that together provide a custom fit to allow OA sufferers to move freely without pain so they can participate in light to heavy activities.

  • Web Tech™ is a shock absorber that assists with full knee extension and patellofemoral (PF) tracking
  • Exos® Tech provides a heat thermoformable custom fit that hugs perfectly around the knee (thigh and the shin or above and below the knee)
  • Boa® Tech uses a micro tension adjustment system that pulls everything together and provides three-dimensional protection

When compared to non-treatment, active use of bracing such as TriFit can slow the progression of Knee OA or other serious knee injuries enabling ongoing activity.

To learn more about your bracing options or to order TriFit, contact your general physician. To see all of DonJoy’s new technologies visit www.djoglobal.com

Individual results may vary.

Neither DJO Global, Inc. nor any of its subsidiaries dispense medical advice. The contents of this press release do not constitute medical, legal, or any other type of professional advice. Information related to various health, medical, and fitness conditions and their treatment is not meant to be a substitute for the advice provided by a physician or other medical professional. You should not use the information contained herein for diagnosing a health or fitness problem or disease. Rather, please consult your healthcare professional for information on the courses of treatment, if any, which may be appropriate for you.

About DJO Global

DJO Global is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMFTM, Compex®, DonJoy®, ProCare®, DJO® Surgical, Dr. Comfort®, Bell-Horn® and ExosTM. For additional information on the Company, please visit www.DJOglobal.com.

Social Media:

Facebook: /donjoy

Twitter: @donjoy

References:

  1. https://www.niams.nih.gov/Health_Info/Osteoarthritis/default.asp
  2. http://www.arthritis.org/about-arthritis/understanding-arthritis/arthritis-statistics-facts.php. Accessed February 15, 2017
  3. https://www.cdc.gov/arthritis/basics/osteoarthritis.htm

Contacts

Chloe Canta (The Brand Amp)
chloe@thebrandamp.com
949.438.1083

Read More
osteoporosis1.jpg

Despite the known role of vitamin D in preventing osteoporosis, less than half of elderly hip fracture patients take supplements

Posted On March 14, 2017 By OrthoSpineNews In Extremities, Spine /  

SAN DIEGO, Calif., March 14, 2017 /PRNewswire-USNewswire/ — Despite national recommendations for daily vitamin D intake, a new study presented today at the 2017 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) found that just 45.7 percent of patients reported consistently taking vitamin D supplements following a hip fracture, a known treatment and preventative strategy for osteoporosis.

In the U.S., an estimated 44 million people have osteoporosis and another 10 million are at risk for the disease which causes progressive bone loss and increased fracture risk. One in two women and one in four men older than age 50 years will sustain a bone fracture caused by osteoporosis. These potentially debilitating injuries include fractures of the hip, spine, wrist, arm or leg, often occurring from a fall. A bone fracture is often the first sign of the disease which develops slowly with no other symptoms. Treatments, which include medication, weight-bearing exercise, and/or vitamin D, calcium or estrogen supplements, can prevent subsequent fractures.

The U.S. Food and Nutrition Board (FNB) at the Institute of Medicine of The National Academies recommends 600 International Units (IUs) of vitamin D each day for adults, and 800 IUs for Americans age 71 and older.

In this study, Canadian researchers interviewed 573 hip fracture patients about their vitamin D intake during doctor visits for two years following hip fracture surgery. The mean patient age was 74.1, and the majority of patients (66.3 percent) were women.

Less than 50 percent (47.5 percent) of the patients consistently took vitamin D supplements as recommended, 35.6 percent took supplements inconsistently, and less than 19 percent took no supplements.  Despite well-developed guidelines and close follow-up in a clinical trial, a low proportion of elderly hip fracture patients are consistently taking vitamin D. This suggests a need to develop and evaluate additional strategies to promote compliance.

“Vitamin D supplementation following hip fracture surgery is grossly under-prescribed,” said co-study author Mohit Bhandari, MD, an orthopaedic surgeon and research chair in musculoskeletal trauma and surgical outcomes, at McMaster University in Ontario, Canada. “Given its potential to improve patient function independent of other therapies, it seems improved advocacy and education—aimed at doctors and patients—about vitamin D supplementation is both worthwhile and evidence-based.”

Added co-study author Earl Bogoch, MD, an orthopaedic surgeon at the University of Toronto: “The benefits, safety and ease of taking vitamin D appear to be unknown or ignored by this representative cohort group of elderly osteoporotic patients who are identified by numerous guidelines as being most likely to benefit.”

The AAOS position statement, “Orthopaedic Care of Patients with Fragility Fractures,” recommends that U.S. physicians proactively screen, monitor, and, if necessary, assist in getting treatment for elderly and other at-risk patients for osteoporosis following an initial bone fracture to prevent subsequent fractures.

Study abstract

2017 AAOS Annual Meeting Disclosure Statements

The American Academy of Orthopaedic Surgeons
With more than 39,000 members, the American Academy of Orthopaedic Surgeons (AAOS) is the world’s largest association of musculoskeletal specialists. The AAOS provides education programs for orthopaedic surgeons and allied health professionals, champions and advances the highest musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments, and related issues.

Visit AAOS at:
Newsroom.aaos.org for bone and joint health news, stats, facts, images and interview requests.
ANationinMotion.org for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery.
Orthoinfo.org for patient information on hundreds of orthopaedic diseases and conditions.
Facebook.com/AAOS1
Twitter.com/AAOS1

This information is being sent to you by:
American Academy of Orthopaedic Surgeons
9400 W. Higgins Road, Rosemont, IL , 60018,
http://www.aaos.org

Read More
EOS1-2_876x300.jpg

New Presentations and Recent Additions to EOS Product Offering to Be Featured at AAOS Annual Meeting

Posted On March 13, 2017 By OrthoSpineNews In Extremities /  

March 13, 2017

PARIS–(BUSINESS WIRE)–EOS imaging (Paris:EOSI)(Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced it will exhibit its full EOSapps software suite at the upcoming American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, being held March 14 – 18 in San Diego, California. The AAOS academic program also includes ten oral podium presentations featuring the EOS imaging technology and software solutions.

EOS imaging will particularly showcase hipEOS, a fully integrated pre-op and post-op 3D simulation and planning software which enables enhanced 3D personalized care for patients. hipEOS addresses several key areas of concern for total hip arthroplasty (THA):

  • Prevention of implant wear, impingement and dislocation risks through personalized implant positioning rather than generic “safe zone” as well as incorporation of functional parameters from standing and seated exams.
  • Prevention of leg length discrepancy, an important area of concern for patient satisfaction and one of the most common reasons for litigation, through the utilization of weight-bearing 3D data to plan length and position.

Marie Meynadier, CEO of EOS imaging, said: “We are pleased to see increasing acknowledgement in the orthopedic field of the value of EOS 3D imaging and planning, as compared to using higher cost, higher dose, supine CT scanning. The podium presentations highlighting EOS system and applications at this year’s AAOS, along with the significant increase in EOS-related publications in peer-reviewed journals in 2016, which doubled from 2015, support this momentum.”

EOS imaging will be onsite at Booth #4933 (Hall G), where the company will showcase the EOS low dose imaging system and its full suite of FDA cleared surgical planning EOSapps solutions, which includes hipEOS, along with spineEOS and kneeEOS. The EOSapps are online 3D surgical simulation and planning solutions, based on unbiased, weight-bearing EOS images and an accurate 2D/3D patient-specific data set.

In addition to the activities at its booth at AAOS, the Company is scheduled to present at the Canaccord Genuity Musculoskeletal Conference on March 14, 2017 at 10:30 am PST. The conference provides the opportunity for institutional investors to meet with the Company.

For more information, please visit www.eos-imaging.com.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

About EOS imaging

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2016 revenues of €30.8 million and employs 132 people at December 2016, including an R&D team of 43 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

Contacts

EOS imaging
Anne Renevot
CFO
Ph: +33 (0)1 55 25 61 24
investors@eos-imaging.com
or
NewCap
Financial communication and investor relations
Pierre Laurent / Valentine Brouchot
Ph: +33 (0)1 44 71 94 96
eosimaging@newcap.fr
or
The Ruth Group (US)
Press relations / Joanna Zimmerman
Ph: 646-536-7006
jzimmerman@theruthgroup.com

Read More
DJO-Global.jpg

DJO Global Announces the Launch of the Altivate™ Anatomic Shoulder System

Posted On March 13, 2017 By OrthoSpineNews In Extremities /  

March 13, 2017

SAN DIEGO–(BUSINESS WIRE)–DJO Global, Inc. (“DJO” or the “Company”), a leading global provider of medical technologies designed to get and keep people moving, today announced the launch of the AltiVate Anatomic Shoulder System. The system features a short, bone sparing humeral stem anatomically designed through morphologically-based fit analysis to optimize metaphyseal fit and stability. The stem also features P2, DJO’s proprietary “porous porous” coating that provides superior bone ingrowth. Coupled with the stem is a glenoid component with patent-pending “Drop and Go™” technology encompassing trilobe features on the peripheral pegs for immediate fixation upon implantation. This data-driven result is a truly anatomic reconstruction with fixation you can feel.

“The AltiVate Anatomic system allows the surgeon to use a short or standard length humeral stem with the same instrument system and introduces a new glenoid component with outstanding initial fixation. The glenoid instrumentation is low profile and user friendly,” states Dr. Gerald Williams of the Rothman Institute and a leading designer of the system. In summary, “this system provides the humeral length you want; the glenoid fixation you need.”

Brady Shirley, President and CEO of DJO Global states, “The release of this new system strengthens our Upper Extremity portfolio, which is already known for its market-leading AltiVate Reverse shoulder system. We believe this will help us sustain our above market growth in this segment. The AltiVate Anatomic is the first of many advancements to come from DJO Global’s developers consisting of world recognized leaders in shoulder arthroplasty.”

This new system will be showcased at this year’s Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS booth #1733) in San Diego, CA.

About DJO Global

DJO Global is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopaedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopaedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, ProCare®, DJO® Surgical, Dr. Comfort® and Exos™. For additional information on the Company, please visit www.DJOglobal.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements relate to, among other things, the Company’s expectations for the success of this product family and its Upper Extremity product portfolio. The words “believe,” “will,” “should,” “expect,” ”target,” “intend,” “estimate” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based on the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions, many of which are beyond the Company’s ability to control or predict. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The important factors that could cause the results of the Company’s new product family and Upper Extremity product portfolio to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the complexities and uncertainties associated with the development of new products; the uncertainties associated with acceptance of the new products by surgeons and patients; new product introduction and other business strategies relative to our Surgical Implant segment; the continued growth of the markets the Company addresses and any impact on these markets from changes in global economic conditions; the impact of potential reductions in reimbursement levels and coverage by Medicare and other governmental and commercial payors; the Company’s highly leveraged financial position; the Company’s ability to successfully develop, license or acquire, and timely introduce and market new products or product enhancements; risks relating to the Company’s international operations; resources needed and risks involved in complying with government regulations and government investigations; the availability and sufficiency of insurance coverage for pending and future product liability claims; and the effects of healthcare reform, Medicare competitive bidding, managed care and buying groups on the prices of the Company’s products. These and other risk factors related to DJO are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission on March 25, 2016. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company’s ability to control or predict.

Contacts

DJO Investor/Media Contact:
DJO Global, Inc.
David Smith
SVP and Treasurer
760-734-3075
ir@djoglobal.com

Read More
1200px-Acumed_headquarters_-_Hillsboro_Oregon.jpg

Acumed LLC Announces Appointment of Sharon Wolfington as President and Chief Executive Officer

Posted On March 13, 2017 By OrthoSpineNews In Extremities /  

HILLSBORO, OREGON (PRWEB) MARCH 10, 2017

Acumed LLC, a member of the Colson Associates, Inc. group of companies and a global leader of innovative orthopaedic medical solutions, today announced the appointment of Sharon Wolfington as president and chief executive officer, effective immediately. Ms. Wolfington succeeds Robert Johnson, who had served as Acumed’s president since 2013.

“We are extremely pleased that Sharon Wolfington is joining Acumed as president and chief executive officer,” said Louhon Tucker, president and chief executive officer of Colson Associates, Inc. “Acumed is an outstanding and highly respected company in the orthopaedic implant market. Sharon’s deep orthopaedic industry experience and her broad market knowledge—combined with her successful leadership roles, her focused approach to market-based product innovation, quality and customer service, her record of building successful and effective sales and distribution networks, and her demonstrated belief in and adherence to ethics, accountability, and employee support and mentoring—makes her the ideal individual to lead Acumed forward. I am confident that Sharon will achieve the company’s objectives of sustainable above-market profitable growth and increasing the pace of providing innovative new products for Acumed’s existing and new customers within the orthopaedic market. As always, it is our intent to ease the burden on orthopaedic and trauma surgeons and further improve the standard of patient care.”

Wolfington joins Acumed after most recently serving as president of DJO Recovery Sciences, a Blackstone company. Previously, Wolfington held a number of significant leadership positions with Stryker Corporation, including president of Stryker Performance Solutions and vice president and general manager of Stryker Global Trauma and Extremities. Wolfington is a graduate of the Advanced Management Program of the Harvard School of Business with an undergraduate degree from Miami University in Oxford, Ohio. She is an honorary founding member of the Foundation of Orthopaedic Trauma.

“I am honored to join the Acumed organization and continue the legacy of high ethics and integrity, quality manufacturing, and new product innovation with the goal of delivering an outstanding customer experience. Acumed is 100% dedicated to serving the foot and ankle, trauma, sports medicine, and hand and upper extremity health care professionals. Acumed has the ability to achieve market-leading growth as an agile, fast moving innovator with highly engaged employees and a best-in-class distributor network,” said Wolfington.

About Acumed

Acumed is a global leader of innovative orthopaedic and medical solutions developed to improve patient care. With over two decades of experience in the orthopaedic industry, our mission is to aid the afflicted through the ingenuity of our minds, the labor of our hands and the compassion of our hearts. Acumed was founded in 1988 by Randy and Mary Huebner and became a member of the Colson Associates group of companies in 1999. The company is headquartered in Hillsboro, Oregon with a global sales and distribution network supported by offices worldwide.

Read More
bonescalpel-wond-1.png

Misonix, Inc. Enters into Exclusive Chinese Distribution Agreement for BoneScalpel

Posted On March 7, 2017 By OrthoSpineNews In Extremities, Spine /  

FARMINGDALE, N.Y., March 7, 2017 /PRNewswire/ — Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it has entered into an exclusive distribution agreement with Shandong Weigao Orthopedic Device Company Limited (“Weigao Orthopedic”), a subsidiary of Shandong Weigao Group Medical Polymer Company Limited (HKSE: 1066).Weigao Orthopedic is a medical device company in China specializing in research and development, production and sale of spine, trauma and joint orthopedic implants devices.

The terms of the distribution agreement grant exclusive rights to Weigao Orthopedic for the sale, marketing and distribution of Misonix’s BoneScalpel in the People’s Republic of China, Hong Kong, and Macau for an initial period of five years.

Mr. Stavros Vizirgianakis, President and Chief Executive Officer of Misonix, said, “We are pleased to enter into this distribution agreement with Weigao Orthopedic, one of the most highly regarded orthopedic and spine surgery device providers in the People’s Republic of China. They have a broad distribution network and relationships with medical institutions that will benefit from the solutions that the BoneScalpel has to offer. We look forward to a mutually beneficial relationship working with Weigao Orthopedic to introduce and embed our products throughout the PRC, Hong Kong and Macau.”

Mr. Gong Jianbo, Chief Executive Officer and Executive Director of Weigao Orthopedic, commented, “We are very pleased with this partnership and for exclusive distribution rights to BoneScalpel. We greatly appreciate the controlled cutting, sparing of soft tissue and the reduction in bleeding that the BoneScalpel provides. Misonix’s ultrasonic bone cutting technology has been quickly gaining the attention of spine surgeons around the world and our team is excited to bring this important technology to surgeons across China.”

Scott Ludecker, Senior Vice President of Global Sales and Marketing, said, “We greatly appreciate the opportunity to work with one of the leaders in the orthopedic industry in the PRC. We have conducted extensive due diligence on identifying a partner for this most important market for our leading-edge ultrasonic surgical tools. It was clear from the beginning that both companies share a common vision for the future of spine surgery and the important role that BoneScalpel plays in enabling better and safer outcomes for surgeons and the patients they treat.”

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

About Shandong Weigao Group
Shandong Weigao Group and its subsidiaries are principally engaged in the research and development, production and sale of single-use medical devices. The Group has a wide range of products, which includes consumables, orthopedic materials, and blood purification consumables and equipment. The Group’s main production facilities are situated in Weihai, Shandong Province. The Group is incorporated in the People’s Republic of China and has an extensive sales network comprising 28 sales offices, 34 customer liaison centers and 222 cities with sales representatives. Shandong Weigao Group has a total customer base of 5,298 (including 3,132 hospitals, 414 blood stations, 643 other medical units and 1,109 distributors).
For more information on Shandong Weigao Group, please visit http://en.weigaogroup.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, the impact of the pending investigation by the Department of Justice and Securities Exchange Commission, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Corporate Contact 

Investor Contact

Misonix Contact:

Joe Diaz                                  

Joseph Dwyer  

Lytham Partners                                   

631-694-9555 

602-889-9700    

invest@misonix.com  

info@misonix.com

 

SOURCE Misonix, Inc.

Read More

Centric Medical™ Announces Initial Cases for Hammertoe Correction System

Posted On March 1, 2017 By OrthoSpineNews In Extremities /  

February 28, 2017

HUNTLEY, Ill.–(BUSINESS WIRE)–Centric Medical, a division of Life Spine, Inc., which focuses on developing surgical implants for the treatment of distal extremity pathology, announced today that the company has successfully completed initial cases with the Hammertoe Correction System. The innovative system offers a dual threaded design and is inserted between the proximal and middle phalanges so that the opposing threads fixate on the phalangeal canal of the toe and compress the joint.

“Centric Medical’s Hammertoe Correction System is the latest in the rapid evolution of permanent implants to improve the results of hammertoe surgery. This outpatient procedure is quick and the Hammertoe System provides excellent fixation and compression to permanently correct hammertoe deformities. Patients no longer need to have pins sticking out the ends of their toes, eliminating the requirement for follow-up surgery,” said Dr. David Friscia of Eisenhower Medical Center in Rancho Mirage, California.

The Hammertoe Correction System is scheduled for a limited release in Q2 of 2017. The initial case follows the news of FDA clearance of Centric Medical’s Metatarsal Hemi Implant. These systems are part of a growing portfolio which includes innovative osteobiologic products, as well as the groundbreaking TARSA-LINK™ Stand-Alone Wedge Fixation System, the market’s first stand-alone osteotomy wedge with built-in fixation. The system was released to the market in September 2016.

About Centric Medical

Centric Medical is dedicated to improving the quality of life for patients with distal extremity symptomatology, increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Centric Medical, which is privately held, is based in Huntley, Illinois.

Contacts

Life Spine, Inc.
Mr. Mariusz Knap
Vice President of Marketing
847-884-6117
mknap@lifespine.com

Read More
Flag_of_the_United_States_and_Italy.png

IPG and Lima Corporate Partner to Support Value Based Care Delivery in the U.S.

Posted On February 25, 2017 By OrthoSpineNews In Extremities, Recon /  

February 24, 2017

ATLANTA–(BUSINESS WIRE)–

IPG, the industry-leading provider of Device Benefit Management solutions, today announced a partnership with Lima Corporate, a global medical device company providing reconstructive and fixation orthopaedic solutions. With a national footprint and focus on the commercial health care market, IPG enables high quality, cost effective surgical care and supports the delivery of value based care for high cost surgical procedures for their health plan clients. This partnership creates significant opportunities to improve surgical outcomes, while reducing overall healthcare costs.

“Lima Corporate is enthusiastic to initiate this collaboration with IPG as it represents a paradigm shift in the medical device market in the U.S. while maintaining access to state-of-the-art devices. Through this agreement, Lima is able to provide key technology, such as our Trabecular Titanium technology used in our hip and shoulder portfolio, which are the only 3D printed devices with 10-years of clinical follow-up,” said Luigi Ferrari, CEO of Lima Corporate.

By bringing transparency, contracting strategy, analytics and surgical expertise related to the delivery of device-intensive surgical procedures, IPG enables surgeons and facilities to successfully make value-based care delivery decisions that drive quality and affordability around surgical procedures through device selection and site of care optimization. As IPG continues to execute on its manufacturer partnership strategy with firms who strategically align with this objective, Lima was identified as an excellent fit.

“IPG is excited about the opportunity to work closely with Lima to bring their high-value technology to IPG’s health plan clients and patients,” said Vince Coppola, President & CEO of IPG. “This relationship will further expand our mission to bring high quality, cost effective surgical solutions to the U.S. healthcare market.”

As a participating manufacturer in IPG’s Device Benefit Management program, Lima will gain access to IPG’s expansive network of direct partnering facilities and surgeons. This agreement will provide greater access for IPG’s customers for high quality shoulder, hip and knee arthroplasty products. Lima has a strong international presence, and the partnership with IPG will enable Lima to significantly drive expansion of their products in the United States.

About Lima Corporate
Lima Corporate is a global medical device company providing reconstructive orthopaedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, Lima Corporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. Lima Corporate’s product range includes large joint revision and primary implants and complete extremities solutions including fixation. For additional information on the Company, please visit www.limacorporate.com.

About IPG
IPG is the leading provider of Device Benefit Management solutions, working with health plans, providers, surgical facilities and patients across the country to improve quality and reduce costs for surgical procedures through optimization of the most effective site of care and device selection, resulting in more affordable high-quality care to consumers. For more information about IPG, call us at 866.753.0046, or visit us on the web at www.ipg.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170224005056/en/

Read More
download.jpeg

Paragon 28® launches robust Charcot and midfoot reconstruction system designed to address deformities of the medial column – Gorilla® Medial Column Plating System

Posted On February 23, 2017 By OrthoSpineNews In Extremities /  

ENGLEWOOD, Colo., Feb. 22, 2017 /PRNewswire/ — Since its inception, Paragon 28 has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28 has launched innovative products and instrumentation that help to streamline procedures, allow surgeons flexibility in technique and approach and facilitate reproducible results benefiting both the surgeon and patient.

The Gorilla® Medial Column Plating System is the latest example of Paragon 28’s commitment to excellence.  The system offers surgeons 36 unique plating options to address varying patient anatomies and levels of deformity and includes plates of varying thickness (1.5 mm and 2.0 mm) to account for size and severity of condition. The plates are constructed from titanium (Ti6AI4V-ELI) for increased strength.  All of the plates accept 2.7, 3.5, and 4.2 mm locking and non-locking polyaxial screws allowing the surgeon to target the highest quality bone around the fracture site.  All plates accept both R3CON™ and TuffNeck™ screw technologies allowing surgeons flexibility to vary the stoutness of the construct to best meet the needs of the patient. Additionally, all holes have a built-in recess to reduce screw head prominence.

Additional Plate Features:

  • Superior holes on the Arch and Proximal Arch plates are tabbed allowing the surgeon to bend the plate to better contour to the talus.
  • Fixed axis screw trajectories are intended to capture the highest quality bone on either side of each fusion site without intersecting.

As is customary with all Paragon 28 systems, this system includes procedure specific instrumentation to facilitate dissection and accurate plate placement.

  • Pin Distractor
    • Allows for greater exposure to joint spaces to aid in removal of osteophytes and cartilage
  • Compression-Distraction Device
    • Attaches on either side of the plate or bone fusion site using two k-wires to create in-line compression or distraction
  • Subchondral Drill
    • For use in arthrodesis joint preparation, the instrument provides approximately 10 mm of controlled drilling of subchondral bone with a stop to help prevent deeper penetration
  • Cartilage Removal Tool
    • Provides “reverse cutting” functionality which is ideal for debridement of curved, small and/or difficult to access joints

Paragon 28 is grateful for the significant contribution Dr. Chris Coetzee, MD made in the design of plates included in this system.

Product Page:
http://www.paragon28.com/products/medial-column-plating-system/

CONTACT:
Jim Edson
jedson@paragon28.com

 

SOURCE Paragon 28, Inc.

Related Links

http://www.paragon28.com

Read More
Bioness-StimRouter.jpg

Bioness Announces First European Implants for StimRouter Neuromodulation System

Posted On February 23, 2017 By OrthoSpineNews In Extremities, Neuro /  

VALENCIA, Calif., Feb. 22, 2017 /PRNewswire/ — Bioness, Inc., the leading provider of cutting edge, clinically supported rehabilitation therapies, today announced the first series of successful StimRouter Neuromodulation System implantations in Europe at Radboud University Medical Center (Nijmegen, Netherlands), South Victoria University (Cork, Ireland), and Kliniek Park Leopold Chirec (Brussels, Belgium). With the successful launch continuing, Bioness plans to further support clinicians across the continent who are looking to support patients seeking minimally-invasive, long-term pain relief.

Erkan Kurt, MD (The Netherlands), Dominic Hegarty, MD (Ireland), and Jean Pierre van Buyten, MD (Belgium) implanted the StimRouter to manage chronic pain conditions originating from varied peripheral neuralgias. With an estimated 100 million Europeans suffering from chronic pain, there has never been a greater need for innovative pain management options.

“For many years we have had limited solutions to help our patients manage their debilitating pain,” shared Dominic Hegarty, MD, a trained Interventional Neuromodulation and Pain Management Specialist. “I’m very pleased to be able to provide the best neuromodulation options for my patients. I am confident that the StimRouter technology will be suitable for a greater range of patients in the future.”

“The StimRouter promises to be a breakthrough in neurostimulation because it is a much smaller device to implant and therefore easier to target pain at its origin,” stated Jean Pierre van Buyten, MD, an internationally renowned Pain Anesthesiologist. “Another advantage is that it minimizes cost and recovery time when compared to other more invasive treatments.”

“Peripheral neuropathy is a very common and often painful disorder. As a neurosurgeon with more than 20 years of neuromodulation experience, the StimRouter provides a unique opportunity to deliver patients relief from chronic pain, especially among those with peripheral nerve damage and scar tissue around the targeted nerve,” explained Erkan Kurt, MD. “Where percutaneous implantation might be a difficult procedure, the StimRouter is a small device that takes a minimally invasive approach that is easy to perform. Another great advantage is the transdermal electrical stimulation which makes implantation of an implantable pulse generator unnecessary.”

As a minimally invasive device designed to reduce pain by specifically targeting the affected peripheral nerve, the StimRouter is intended to be a cost-effective and long-term alternative to immobilization, injections, and prescription opioids. The implant procedure is usually completed in less than 30 minutes and uses only local anesthesia.

“As we continue to see impressive clinical results in the US and now Europe we are excited to further our mission of supporting clinicians looking to improve the lives of patients,” said Todd Cushman, President and CEO of Bioness. “Patients and their loved ones are looking for true relief from the downward spiral of chronic pain. With greater awareness of opioid addiction, alternative choices which deliver life improving results are needed. We are thrilled to be bringing expanded treatment options to those who care for patients.”

StimRouter was the first FDA cleared minimally-invasive, long-term, minimally invasive neuromodulation medical device indicated to treat chronic pain of a peripheral nerve origin. The StimRouter System then received CE mark in February of 2014 and the Company began expanding its focus into the European Union. The patient controlled medical device is an adjunct to other modes of therapy and is being well received by patients and clinicians alike.

The StimRouter is currently being implanted at prestigious clinical institutions across the United States to treat chronic peripheral nerve pain, with specific focus on the following conditions or areas:

  • Axillary nerve (e.g. post-stroke shoulder pain)
  • Ulnar nerve (e.g. cubital tunnel syndrome)
  • Suprascapular
  • Superior Cluneal nerve (e.g. lower back neuralgia)
  • Genicular nerve
  • Median nerve
  • Peroneal nerves

For more information on the StimRouter as well as videos of real patients sharing their StimRouter experience, please visit www.stimrouter.com.

About StimRouter™ Neuromodulation System

StimRouter is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive neuromodulation medical device consisting of a thin, implanted lead with conductive electrode, external pulse transmitter (EPT), and hand-held wireless patient programmer. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. StimRouter is programmed at the direction of the physician to meet patient requirements but is controlled by the patient to address the patients specific, changing pain management needs.

About Bioness, Inc.

Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include implantable and external neuromodulation systems, robotic systems and software based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries. Currently, Bioness offers six medical devices within its commercial portfolio which are distributed and sold on five continents and in over 25 countries worldwide. Bioness innovations have been implemented in the most prestigious and well-respected institutions around the globe with 17 of the top 20 rehabilitation hospitals in the United States currently using one or more Bioness solution. Bioness has a singular focus on aiding large, underserved customer groups with innovative, evidence-based solutions and we will continue to develop and make commercially available new products that address the growing and changing needs of our customers. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at www.bioness.com.

Media Relations Contact Information
Next Step Communications
bioness@nextstepcomms.com
781.326.1741

StimRouter™ and Bioness® are trademarks of Bioness, Inc. | www.bioness.com | Rx Only | Additional information about StimRouter can be found at www.stimrouter.com

SOURCE Bioness, Inc.

Related Links

http://www.bioness.com

Read More